Abbott LaboratoriesvsUroGen Pharma

ABT and URGN stock compared: price, dividend, valuation and results, from SEC filings.

ABT

Abbott Laboratories

$103.87

Value $180B

-0.58%
ABT's page

Abbott Laboratories (ABT) has a market value of $180B and UroGen Pharma (URGN) $1.5B. Over the last year, with dividends, ABT moved -18.1% and URGN +34.7%. Dividend yield: ABT 2.43%, URGN none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABT$180B

    URGN$1.5B

    ABT is 117 times URGN

  • Revenue, 12 months

    ABT$48.2B

    URGN$250M

    ABT is 193 times URGN

  • Net income, 12 months

    ABT$4.7B

    URGN-$66M

  • Operating margin

    ABT13.8%

    URGN-12.4%

    26.2 points apart

  • ROIC

    ABT6.3%

    URGN-58.4%

    64.7 points apart

  • P/E

    ABT38.4

    URGN–

  • Dividend yield

    ABT2.4%

    URGN0.0%

    2.4 points apart

  • 5-year return

    ABT-10.1%

    URGN+153.4%

    163.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABT-10.1%

URGN+153.4%

20040020222023202420252026
Returns by period
PeriodABTWith dividendsURGNWith dividends
1 year since November 18, 2025-18.1%Price -20.1%+34.7%Price +34.7%
3 years since November 17, 2023+11.1%+3.6% a yearPrice +4.3%+154.7%+36.6% a yearPrice +154.7%
5 years since November 18, 2021-10.1%-2.1% a yearPrice -18.6%+153.4%+20.4% a yearPrice +153.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABTAbbott LaboratoriesURGNUroGen Pharma

Valuation

ABTURGN
Valuation
Price$103.87$31.73
Market value$180B$1.5B
Enterprise value (EV)$207B$1.6B
P/E38.4–
P/E, 5-year median33.7–
P/B3.5–
EV/EBIT31.2–
Free cash flow yield3.7%–

Results and growth

ABTURGN
Results and growth
Revenue, 12 months$48.2B$250M
Net income, 12 months$4.7B-$66M
Free cash flow, 12 months$6.8B-$132M
Earnings per share, 12 months$2.69-$1.31
Revenue growth, year on year5.7%21.5%
Revenue growth a year, past+5.1%over 5 years+56.2%over 5 years
EPS growth a year, past+8.3%over 5 years–

Margins and returns on capital

ABTURGN
Margins and returns on capital
Gross margin56.9%91.4%
Operating margin13.8%-12.4%
Net margin9.8%-26.3%
ROIC6.3%-58.4%
ROE9.1%–

Balance sheet

ABTURGN
Balance sheet
Cash$4.3B$91M
Total debt$31.2B$196M
Net debt / EBITDA3.3–
Interest cover6.7×–

Dividends and buybacks

ABTURGN
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$2.52–
Dividend growth a year, past+10.4%over 5 years–
Buyback yield0.5%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABT or URGN

Didn't find what you were looking for?

Ask us
Which is bigger, Abbott Laboratories or UroGen Pharma?

By market value, Abbott Laboratories ($180B) is about 116.8 times UroGen Pharma ($1.5B), at today's prices.

How did ABT and URGN stock do over the last 5 years?

Since November 18, 2021, ABT's price moved -18.6% and URGN's +153.4%. With dividends: ABT -10.1% (-2.1% a year), URGN +153.4% (+20.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABT or URGN?

The dividend yield at today's price is 2.43% for Abbott Laboratories and none for UroGen Pharma. Over the last twelve months they paid $2.52 and – per share.

Which has the higher profit margins, Abbott Laboratories or UroGen Pharma?

Over the last twelve months, the net margin was 9.8% for Abbott Laboratories and -26.3% for UroGen Pharma, and the operating margin 13.8% and -12.4%. Revenue was $48.2B and $250M.

Which is the better investment, Abbott Laboratories or UroGen Pharma?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.